Trinity Price To Sales Ratio vs Payout Ratio Analysis

TRIB Stock

USD 1.12 0.01 0.88%

Trinity Biotech financial indicator trend analysis is much more than just breaking down Trinity Biotech plc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Trinity Biotech plc is a good investment. Please check the relationship between Trinity Biotech Price To Sales Ratio and its Payout Ratio accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Price To Sales Ratio vs Payout Ratio

Price To Sales Ratio vs Payout Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Trinity Biotech plc Price To Sales Ratio account and Payout Ratio. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Trinity Biotech's Price To Sales Ratio and Payout Ratio is -0.3. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Payout Ratio in the same time period over historical financial statements of Trinity Biotech plc, assuming nothing else is changed. The correlation between historical values of Trinity Biotech's Price To Sales Ratio and Payout Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Trinity Biotech plc are associated (or correlated) with its Payout Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Payout Ratio has no effect on the direction of Price To Sales Ratio i.e., Trinity Biotech's Price To Sales Ratio and Payout Ratio go up and down completely randomly.

Correlation Coefficient

-0.3

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Trinity Biotech plc stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Trinity Biotech sales, a figure that is much harder to manipulate than other Trinity Biotech plc multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Payout Ratio

Payout Ratio is the proportion of Trinity Biotech plc earnings paid out as dividends to shareholders. Payout Ratio is typically expressed as a percentage but can be shown as dividends paid out as a proportion of cash flow. The payout ratio is used to determine the sustainability of Trinity Biotech plc dividend payments. A lower payout ratio is generally preferable to a higher payout ratio, with a ratio greater than 100% indicating Trinity Biotech plc is paying out more in dividends than it makes in net income.

Most indicators from Trinity Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Trinity Biotech plc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

As of November 27, 2024, Selling General Administrative is expected to decline to about 23.8 M. In addition to that, Discontinued Operations is expected to decline to about (65.2 K)

	2021	2022	2023	2024 (projected)
Total Revenue	93.0M	74.8M	56.8M	78.6M
Depreciation And Amortization	2.7M	2.3M	1.8M	1.7M

Total Revenue Depreciation And Amortization

Trinity Biotech fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock Total Equity	Property Plant And Equipment Gross	Common Stock
Total Assets		0.55	-0.03	0.01	0.86	0.92	-0.44	0.86	0.81	0.76	0.94	0.87	0.76	0.72	0.37	0.35	0.68	-0.05	-0.41	0.33	0.85	-0.07	0.94	0.46	-0.47	0.01
Short Long Term Debt Total	0.55		0.22	0.36	0.22	0.54	0.25	0.25	0.58	0.22	0.54	0.44	0.22	0.54	0.38	0.51	0.8	-0.09	-0.3	0.64	0.41	0.26	0.54	0.67	-0.12	0.28
Other Current Liab	-0.03	0.22		0.21	0.13	0.11	-0.07	0.13	-0.24	-0.37	0.15	0.13	-0.37	-0.03	0.68	-0.42	0.02	-0.15	-0.03	-0.3	-0.3	0.31	0.11	0.26	0.37	0.35
Total Current Liabilities	0.01	0.36	0.21		-0.19	0.01	0.37	-0.12	-0.08	-0.03	-0.03	-0.16	-0.03	0.06	-0.09	-0.1	0.33	-0.07	-0.31	0.37	0.07	0.96	-0.04	0.27	0.41	0.08
Total Stockholder Equity	0.86	0.22	0.13	-0.19		0.82	-0.8	0.99	0.66	0.64	0.87	0.91	0.64	0.5	0.61	-0.12	0.31	-0.02	-0.4	-0.2	0.63	-0.14	0.85	0.16	-0.54	-0.19
Property Plant And Equipment Net	0.92	0.54	0.11	0.01	0.82		-0.37	0.83	0.73	0.54	0.96	0.76	0.54	0.66	0.44	0.28	0.63	0.1	-0.33	0.26	0.65	-0.04	0.94	0.37	-0.43	-0.02
Net Debt	-0.44	0.25	-0.07	0.37	-0.8	-0.37		-0.79	-0.26	-0.52	-0.42	-0.62	-0.52	-0.04	-0.5	0.49	0.24	0.01	0.35	0.63	-0.33	0.22	-0.39	0.23	0.5	0.35
Retained Earnings	0.86	0.25	0.13	-0.12	0.99	0.83	-0.79		0.65	0.65	0.86	0.88	0.65	0.51	0.59	-0.13	0.32	0.01	-0.49	-0.18	0.64	-0.07	0.83	0.15	-0.58	-0.24
Accounts Payable	0.81	0.58	-0.24	-0.08	0.66	0.73	-0.26	0.65		0.52	0.78	0.81	0.52	0.74	0.34	0.42	0.71	0.02	-0.34	0.36	0.66	-0.17	0.77	0.44	-0.59	-0.03
Cash	0.76	0.22	-0.37	-0.03	0.64	0.54	-0.52	0.65	0.52		0.53	0.58	1.0	0.42	-0.03	0.31	0.33	-0.13	-0.49	0.28	0.92	-0.12	0.53	0.21	-0.46	-0.12
Non Current Assets Total	0.94	0.54	0.15	-0.03	0.87	0.96	-0.42	0.86	0.78	0.53		0.88	0.53	0.65	0.55	0.22	0.62	-0.02	-0.29	0.19	0.64	-0.06	0.99	0.38	-0.41	-0.01
Non Currrent Assets Other	0.87	0.44	0.13	-0.16	0.91	0.76	-0.62	0.88	0.81	0.58	0.88		0.58	0.59	0.66	0.05	0.49	-0.15	-0.38	-0.03	0.64	-0.16	0.88	0.32	-0.52	-0.08
Cash And Short Term Investments	0.76	0.22	-0.37	-0.03	0.64	0.54	-0.52	0.65	0.52	1.0	0.53	0.58		0.42	-0.03	0.31	0.33	-0.13	-0.49	0.28	0.92	-0.12	0.53	0.21	-0.46	-0.12
Net Receivables	0.72	0.54	-0.03	0.06	0.5	0.66	-0.04	0.51	0.74	0.42	0.65	0.59	0.42		0.21	0.46	0.88	0.2	-0.2	0.46	0.7	-0.11	0.63	0.68	-0.35	0.17
Common Stock Shares Outstanding	0.37	0.38	0.68	-0.09	0.61	0.44	-0.5	0.59	0.34	-0.03	0.55	0.66	-0.03	0.21		-0.4	0.19	-0.05	-0.1	-0.42	0.04	0.04	0.52	0.23	-0.11	0.08
Non Current Liabilities Total	0.35	0.51	-0.42	-0.1	-0.12	0.28	0.49	-0.13	0.42	0.31	0.22	0.05	0.31	0.46	-0.4		0.6	-0.02	0.06	0.89	0.45	-0.33	0.25	0.49	-0.13	0.36
Inventory	0.68	0.8	0.02	0.33	0.31	0.63	0.24	0.32	0.71	0.33	0.62	0.49	0.33	0.88	0.19	0.6		0.02	-0.15	0.71	0.65	0.13	0.63	0.79	-0.09	0.33
Other Current Assets	-0.05	-0.09	-0.15	-0.07	-0.02	0.1	0.01	0.01	0.02	-0.13	-0.02	-0.15	-0.13	0.2	-0.05	-0.02	0.02		0.36	-0.05	-0.07	-0.05	-0.05	0.04	-0.05	0.01
Other Stockholder Equity	-0.41	-0.3	-0.03	-0.31	-0.4	-0.33	0.35	-0.49	-0.34	-0.49	-0.29	-0.38	-0.49	-0.2	-0.1	0.06	-0.15	0.36		-0.09	-0.37	-0.34	-0.24	-0.04	0.58	0.36
Total Liab	0.33	0.64	-0.3	0.37	-0.2	0.26	0.63	-0.18	0.36	0.28	0.19	-0.03	0.28	0.46	-0.42	0.89	0.71	-0.05	-0.09		0.45	0.13	0.22	0.58	0.07	0.37
Total Current Assets	0.85	0.41	-0.3	0.07	0.63	0.65	-0.33	0.64	0.66	0.92	0.64	0.64	0.92	0.7	0.04	0.45	0.65	-0.07	-0.37	0.45		-0.1	0.64	0.45	-0.38	0.01
Short Term Debt	-0.07	0.26	0.31	0.96	-0.14	-0.04	0.22	-0.07	-0.17	-0.12	-0.06	-0.16	-0.12	-0.11	0.04	-0.33	0.13	-0.05	-0.34	0.13	-0.1		-0.08	0.12	0.38	-0.02
Intangible Assets	0.94	0.54	0.11	-0.04	0.85	0.94	-0.39	0.83	0.77	0.53	0.99	0.88	0.53	0.63	0.52	0.25	0.63	-0.05	-0.24	0.22	0.64	-0.08		0.39	-0.38	0.01
Common Stock Total Equity	0.46	0.67	0.26	0.27	0.16	0.37	0.23	0.15	0.44	0.21	0.38	0.32	0.21	0.68	0.23	0.49	0.79	0.04	-0.04	0.58	0.45	0.12	0.39		0.2	0.77
Property Plant And Equipment Gross	-0.47	-0.12	0.37	0.41	-0.54	-0.43	0.5	-0.58	-0.59	-0.46	-0.41	-0.52	-0.46	-0.35	-0.11	-0.13	-0.09	-0.05	0.58	0.07	-0.38	0.38	-0.38	0.2		0.58
Common Stock	0.01	0.28	0.35	0.08	-0.19	-0.02	0.35	-0.24	-0.03	-0.12	-0.01	-0.08	-0.12	0.17	0.08	0.36	0.33	0.01	0.36	0.37	0.01	-0.02	0.01	0.77	0.58

Click cells to compare fundamentals

Trinity Biotech Account Relationship Matchups

Trinity Biotech fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	131.1M	130.4M	118.9M	92.1M	59.4M	56.5M
Short Long Term Debt Total	102.2M	104.3M	99.2M	58.3M	67.4M	42.8M
Other Current Liab	(2.6M)	9.6M	7.9M	9.1M	8.9M	4.7M
Total Current Liabilities	19.4M	27.1M	100.5M	17.3M	15.0M	22.6M
Total Stockholder Equity	4.7M	(2.2M)	(319K)	(2.2M)	(23.9M)	(22.8M)
Property Plant And Equipment Net	9.3M	8.5M	5.9M	5.7M	1.9M	1.8M
Net Debt	65.6M	77.0M	73.2M	51.7M	63.7M	66.9M
Retained Earnings	11.5M	10.6M	12.6M	(26.7M)	(48.6M)	(46.2M)
Accounts Payable	19.4M	7.1M	6.8M	6.2M	3.9M	3.7M
Cash	16.4M	27.3M	25.9M	6.6M	3.7M	3.5M
Non Current Assets Total	59.7M	47.1M	46.2M	45.4M	20.4M	19.4M
Non Currrent Assets Other	82K	64K	56K	55K	43K	40.9K
Cash And Short Term Investments	16.4M	27.3M	25.9M	6.6M	3.7M	3.5M
Net Receivables	23.0M	24.6M	15.7M	13.4M	13.4M	18.1M
Common Stock Shares Outstanding	5.1M	4.2M	5.3M	7.8M	7.7M	6.8M
Liabilities And Stockholders Equity	131.1M	130.4M	118.9M	92.1M	59.4M	56.5M
Non Current Liabilities Total	106.9M	105.6M	18.7M	76.9M	68.3M	39.2M
Inventory	32.0M	30.2M	29.1M	22.5M	19.9M	25.5M
Other Current Assets	23.0M	1.2M	1.9M	4.1M	2.0M	3.9M
Total Liab	126.4M	132.6M	119.2M	94.3M	83.4M	61.7M
Total Current Assets	71.4M	83.3M	72.7M	46.7M	39.0M	69.5M
Short Term Debt	2.4M	5.1M	85.3M	1.9M	1.9M	1.8M
Intangible Assets	31.1M	21.3M	23.4M	22.7M	16.3M	15.5M
Property Plant And Equipment Gross	9.3M	8.5M	63.5M	65.6M	66.1M	69.4M
Accumulated Other Comprehensive Income	(24.2M)	(5.3M)	(5.4M)	(5.7M)	1.0M	1.1M
Long Term Debt	81.4M	82.0M	83.9M	58.0M	54.7M	44.0M
Property Plant Equipment	5.4M	9.3M	8.5M	5.9M	5.3M	9.6M
Other Liab	8.1M	7.1M	6.3M	4.9M	5.6M	6.2M
Current Deferred Revenue	292K	4.4M	141K	114K	50K	47.5K
Other Assets	33.0M	29.5M	18.1M	4.3M	5.0M	4.7M
Net Tangible Assets	17.4M	(16.2M)	(22.6M)	(36.3M)	(32.7M)	(31.0M)
Deferred Long Term Liab	26.3M	22.8M	13.4M	17.7M	15.9M	15.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

When determining whether Trinity Biotech plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Trinity Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Trinity Biotech Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Trinity Biotech Plc Stock:

How To Invest In Trinity

Details

Is Trinity Stock a good investment?

Details

What is Trinity Biotech's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Trinity Biotech plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Trinity Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.77)

Earnings Share

(2.25)

Revenue Per Share

6.968

Quarterly Revenue Growth

0.14

Return On Assets

(0.1)

The market value of Trinity Biotech plc is measured differently than its book value, which is the value of Trinity that is recorded on the company's balance sheet. Investors also form their own opinion of Trinity Biotech's value that differs from its market value or its book value, called intrinsic value, which is Trinity Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Trinity Biotech's market value can be influenced by many factors that don't directly affect Trinity Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Trinity Price To Sales Ratio vs Payout Ratio Analysis

Price To Sales Ratio vs Payout Ratio

Price To Sales Ratio vs Payout Ratio Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Payout Ratio

Trinity Biotech fundamental ratios Correlations

Trinity Biotech Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Trinity Biotech fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Retained Earnings	+ 0.99	Total Stockholder Equity
Intangible Assets	+ 0.99	Non Current Assets Total
Short Term Debt	+ 0.96	Total Current Liabilities
Non Current Assets Total	+ 0.96	Property Plant And Equipment Net
Non Current Assets Total	+ 0.94	Total Assets

Net Debt	- 0.8	Total Stockholder Equity
Retained Earnings	- 0.79	Net Debt
Non Currrent Assets Other	- 0.62	Net Debt
Property Plant And Equipment Gross	- 0.59	Accounts Payable
Property Plant And Equipment Gross	- 0.58	Retained Earnings
Property Plant And Equipment Gross	- 0.54	Total Stockholder Equity